Warning letter
Empower Clinic Services, LLC dba Empower Pharmacy: warning letter of Sep 18, 2026
FDA warning letter 738238 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 738238 |
|---|---|
| Company | Empower Clinic Services, LLC dba Empower Pharmacy |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug |
| Issue date | Sep 18, 2026 |
| Posted date | Sep 22, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 211.113(b), 200.10(b), 201.115, 211.22, 211.42(c)(10)(iv), 211.42(c)(10)(vi), 211.100(a), 210.1(b) |
| Inspection city | Houston |
| Inspection ZIP | 77064 |
| Inspection start date | Nov 3, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: